Revenue in the first quarter of 2014 also included $0.3 million of sales of pre-commercial pen injector gadgets to Teva. Additionally, in the three months ended March 31, 2014, the Company recognized net product sales of $0. In the first quarter of 2014, the business delivered $2. Revenue in the first quarter of 2013 included $0.5 million of product sales of our topical oxybutynin gel 3 percent product to Actavis in connection with their advertising of Gelnique 3 percent. Related StoriesPhase II psoriasis study displays efficacy of Boehringer Ingelheim's BI 655066 over ustekinumabResearchers develop novel technology for chronic arthritisACR releases 2015 Guideline for Treatment of Rheumatoid ArthritisDevelopment revenues were $1.4 million and $0.8 million for the 90 days ended March 31, 2014 and 2013, respectively.Based on JUPITER’s findings, the U.S. Meals and Drug Administration recently licensed the use of rosuvastatin to prevent coronary disease in men over 50 years and ladies over 60 years who have one other risk aspect and CRP higher than 2mg/L. The difference in average people CRP ideals in populations of different ancestry are sufficiently large as to have bearing on clinical management and statin eligibility based on single CRP cut-point ideals, said Tina Shah, Ph.D.